The United Kingdom and the United States have finalized a major trade agreement that will keep no levies on British drug exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on medicines through the public health system. This pledge secures that tariffs on these vital exports will stay at zero for a timeframe of 36 months.
This deal is in response to recent threats to significantly raise duties on branded drug imports, with potential rates floated up to double the cost.
"This arrangement with the United Kingdom strengthens the international landscape for innovative medicines and brings long-overdue equity to transatlantic medicine commerce," an announcement declared.
Commercial Significance
Medicines are one of the Britain's largest exports to the United States, which is by far the biggest destination for large British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This amount made up a significant portion of total UK exports in that period.
"This deal safeguards jobs, increases investment and facilitates the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The pact includes several notable commitments from the British government:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to increase total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be limited at 15%. Previously, repayments topped 20%.
Recent Tensions
The pact takes place against a protracted tension between the sector and the UK government over spending levels and approval rates.
The disagreement were heightened by arguments that US patients were charged several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the last ten years.
